Nutraceutical Capsule & Tablet Manufacturing
Quick Summary
- Most of the amino acid, vitamin, and mineral ingredients in the YNP catalogue are suitable for capsule or tablet formats — but the specific salt form, particle size, and hygroscopicity of each ingredient significantly affects manufacturing performance
- Silicon Dioxide (INS 551, Germany-sourced in the YNP catalogue) is the primary flow and anti-caking agent for powdered capsule blends
- Dosing calculations must account for salt form molecular weight — the active ingredient content per gram differs between base and salt forms
- Moisture-sensitive ingredients (L-Carnitine Base, certain amino acids, Vitamin C) require capsule-level moisture barrier and controlled manufacturing environment
Key YNP Ingredients by Capsule/Tablet Role
| Ingredient | Role in solid dosage | Key manufacturing consideration |
|---|---|---|
| Silicon Dioxide | Flow agent, anti-caking, capsule fill | Use at 0.5–2% w/w; Germany-sourced food-grade amorphous form |
| L-Carnitine Base | Active ingredient | Highly hygroscopic — use only in sealed capsules; L-Tartrate preferred for tablet compression |
| L-Carnitine L-Tartrate | Active ingredient | Low hygroscopicity — preferred for tablets and capsules |
| Creatine Monohydrate | Active ingredient | Standard and micronized grades; good flow in capsule fill |
| Beta-Alanine | Active ingredient | Good flow; paraesthesia risk from poor dose uniformity — blend thoroughly |
| Ascorbic Acid | Active ingredient / antioxidant | Moisture and oxidation sensitive — encapsulate with desiccant or use encapsulated (coated) form |
| Magnesium L-Threonate | Active ingredient (mineral) | Low elemental Mg per gram — affects capsule count for target Mg dose |
| Biotin | Active ingredient (vitamin) | High-potency — typically pre-diluted in a carrier before blending to enable accurate dosing |
| Choline Bitartrate | Active ingredient | Good flow; calculate dose as choline equivalents, not total salt weight |
| BCAA 2:1:1 | Active ingredient | Leucine has poor flow characteristics — silicon dioxide addition recommended |
*(Table is horizontally scrollable on mobile)*
Critical Manufacturing Principles
Dosing in active equivalents, not total salt weight. Every amino acid salt, vitamin salt, or mineral salt provides less active ingredient per gram than its molecular weight alone. Before finalising a capsule formula, calculate the dose of each ingredient as the active equivalent. Examples:
- L-Carnitine L-Tartrate: ~68% L-Carnitine equivalent
- Choline Bitartrate: ~41% choline equivalent
- Magnesium L-Threonate: confirm elemental Mg % on COA
- Ascorbic Acid: ~100% Vitamin C equivalent (it is the pure vitamin form)
Blend uniformity is the key quality variable. Content uniformity — ensuring that every capsule contains the same dose of active ingredients within acceptable variation — depends on particle size compatibility between the active and excipient powders. When particle sizes are very different (fine vitamins mixed with coarser amino acids), larger particles tend to segregate to the bottom. Solutions: pre-blend fine ingredients with a coarser carrier; use silicon dioxide to reduce interparticle adhesion; consult a pharmaceutical excipient specialist for complex blends.
Hygroscopic ingredients need environmental controls. L-Carnitine Base, certain BCAAs, and Vitamin C can absorb enough ambient humidity during open processing to cause clumping before capsule filling. Manufacturing in a humidity-controlled environment (typically <45% relative humidity) is standard practice when handling these ingredients.
Capsule selection: gelatin vs HPMC. Standard capsules are gelatin (from bovine or porcine hide/bone). HPMC (hydroxypropyl methylcellulose) capsules are the vegetarian/vegan alternative. If the product will be positioned as vegan, all encapsulating materials must be plant-derived — confirm capsule type before label copy is finalised.
Tablet-Specific Considerations
Tablet compression introduces compaction force on the ingredient blend. Not all amino acids compress well — some are brittle and tablet poorly without modification. Wet granulation (converting the powder blend into granules before compression) improves compressibility of difficult amino acids. L-Carnitine L-Tartrate and Creatine Monohydrate are generally tablettable; L-Leucine and some vitamins benefit from granulation.
Buyer Checklist
- Active equivalent dose calculated for each salt-form ingredient (not total salt weight)
- Silicon Dioxide (0.5–2% w/w) included in blend for hygroscopic amino acids
- Manufacturing environment humidity confirmed (<45% RH where hygroscopic ingredients are processed)
- Capsule type confirmed (gelatin vs HPMC) against product's vegan/vegetarian claim requirements
- COA for all active ingredients confirms particle size range (relevant for blend uniformity)
- Blend uniformity testing protocol confirmed before scale-up
Frequently Asked Questions
Related Products
Related Glossary Terms
Related Downloads
References
Company Information
- YNP Ingredients, Silicon Dioxide, L-Carnitine L-Tartrate, Creatine Monohydrate, Beta-Alanine, Biotin, Choline Bitartrate product pages, ynpingredients.com
Industry Information
- USP. *<905> Uniformity of Dosage Units.* United States Pharmacopeia — standard for content uniformity in capsules and tablets.
- FDA. *21 CFR 172.480 — Silicon dioxide.* GRAS at ≤2% in food.
- Rowe RC, Sheskey PJ, Cook WG, Fenton ME (eds). *Handbook of Pharmaceutical Excipients.* 7th edition. Pharmaceutical Press — standard reference for excipient properties in solid dosage formulation.